Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cecolin vs Gardasil 2-Dose Regimens in Girls
NCT04508309Phase 3Completed
- Sponsor
- PATH
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine in Cervical Cancer (CC), sponsored by PATH. Started Mar 2021; status: completed.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04508309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508309.